Neurosense Therapeutics is trading at $1.59, up 11.97%, alongside an active biotech-sector rally.
- XBI was up 2.05% during the regular session.
- Election-related optimism about reduced drug-pricing concerns and stronger biotech sentiment is supporting the sector, but is not a confirmed company-specific catalyst.
- No new company-specific announcement explaining the November 5 move was identified. The latest identified company news concerns the upcoming Nasdaq hearing and PrimeC milestones, not a new event today.